CGMP Psilocin

(+)-Cloprostenol is the active enantiomer of Cloprostenol. Cloprostenol is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. The ASMF for (+)-Cloprostenol (sodium salt) is on file in several EU member states.

Bimatoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. The DMF is on file with the US FDA, Brazil, Canada and India.

Epoprostenol is a potent vasodilator and antiplatelet substance with a very short physiological half-life. It is used for the treatment of pulmonary hypertension. The DMF for Epoprostenol Sodium Salt is on file with the US FDA, Canada, Japan, Australia, Switzerland and most EU member states.

Cloprostenol sodium salt is used in veterinary medicine as a luteolytic agent for the induction of estrus and the treatment of reproductive disorders in cattle, swine, and horses. Cloprostenol sodium salt is manufactured at Cayman Pharma both in racemic form (CAS No.: 55028-72-3) and optically active form ...

Latanoprost is the most widely used prostaglandin for the treatment of elevated intraocular pressure in glaucoma. Latanoprost is manufactured at Cayman Chemical (Ann Arbor, MI, USA) and at Cayman Pharma (Czech Republic). GMP material from both Cayman Chemical and Cayman Pharma, which conforms to the USP, E...

Latanoprostene Bunod is a nitric oxide-donating FP receptor agonist; it can be used for the treatment of elevated intraocular pressure (IOP) in glaucoma. Latanoprostene Bunod is manufactured at Cayman Pharma, our Czech subsidiary. GMP material is available, and the DMF for Latanoprostene Bunod is available...

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Synthetic and natural forms of psilocybin are currently being studied in numerous clinical trials for the treatment of depression, anxiety, and other mental health conditions. Psilocybin is ...

ANN ARBOR, MI, SEPTEMBER 12, 2023—Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a Certification of Suitability to the monographs of the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its latanoprost API, effective August 28th, 2023. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost.

This leaflet presents cGMP API portfolio of Cayman Pharma and Cayman Chemical.

This leaflet presents services offered by Cayman Chemical.

This leaflet presents detailed overview of cGMP prostaglandins used for glaucoma treatment manufactured by Cayman Pharma and Cayman Chemical.

This leaflet presents detailed overview of cGMP psychedelic APIs manufactured by Cayman Chemical.

This leaflet presents detailed overview of cGMP prostaglandins used for pulmonary hypertension treatment manufactured by Cayman Pharma

This leaflet presents detailed overview of cGMP prostaglandins used in veterinary medicine and manufactured by Cayman Pharma

Learn more about the importance of process understanding and Cayman's commercial API production

Cayman Chemical’s API Services group helps companies turn their new drug ideas into reality. The Cayman advantage offers the flexibility to support your project, allowing you to create a customized service to meet your needs.

The natural compound prostaglandin F2α (PGF2α) activates signaling pathways in the eye that reduce intraocular pressure (IOP). A family of PGF2α analogs, including bimatoprost, latanoprost, tafluprost, and travoprost, have been developed, and these compounds are more potent than PGF2α itself in lowering IOP and have fewer side effects. Moreover, they are known to be safe and effective when used in the treatment of glaucoma.

Psychedelics are emerging as promising therapies in the treatment of various neurological and psychiatric conditions. Though psychedelics are controlled substances in most countries, clinical trials exploring the use of psychedelics are underway. The US FDA has granted breakthrough therapy status for the use of psilocybin in major depressive disorder and treatment-resistant depression, for which it has shown to be safe and effective. It may also have potential in the treatment of anxiety, substance use disorder, cluster headaches, as well as psychological distress associated with end-of-life.

Each prostaglandin (PG) evokes distinct physiological effects through specific cell surface receptors. PGI2 (prostacyclin) promotes smooth muscle relaxation and inhibits platelet activation through the IP receptor. Agonists of IP, including epoprostenol, iloprost, and treprostinil, are effective in relaxing pulmonary arterial smooth muscle and are used in the treatment of pulmonary hypertension.

A stable and potent analog of prostaglandin F2α (PGF2α), cloprostenol is used in the care of domestic mammals to induce luteolysis, initiate estrus, and synchronize estrus cycles. Both the racemic and active isomer are also used to induce parturition, terminate abnormal and normal pregnancies, and treat chronic endometriosis and ovarian luteal cysts.